Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
RECURSION PHARMACEUTICALS, INC. (RXRX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/02/2023 8-K Quarterly results
08/08/2023 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits  I...
Docs: "Recursion Provides Business Updates and Reports Second Quarter 2023 Financial Results",
"Recursion Bridges the Protein and Chemical Space with Massive Protein-Ligand Interaction Predictions Spanning 36 Billion Compounds",
"Decoding Biology To Radically Improve Lives End of Q2, 2023"
07/12/2023 8-K Quarterly results
06/13/2023 8-K Investor presentation
Docs: "of the Securities Litigation Reform Act of 1995. These"
06/09/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "REGISTRATION AGREEMENT",
"AUSTIN BEIJING BOSTON BRUSSELS HONG KONG LONDON LOS ANGELES NEW YORK PALO ALTO SAN DIEGO SAN FRANCISCO SEATTLE SHANGHAI WASHINGTON, DC WILMINGTON, DE"
05/25/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
05/16/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Recursion Appoints David Mauro, M.D., Ph.D.,"
05/08/2023 8-K Quarterly results
05/08/2023 8-K Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits  Interac...
Docs: "SALT LAKE CITY, TORONTO"
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
02/27/2023 8-K Investor presentation
Docs: "Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2022 Financial Results",
"End of Q4 2022"
01/25/2023 8-K Other Events  Interactive Data
Docs: "7 0.1 1 10 20201962 1970 1980 1990 2000 2010"
01/13/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
01/10/2023 8-K Investor presentation
Docs: "Investor presentation of Recursion Pharmaceuticals, Inc."
11/08/2022 8-K Quarterly results
10/25/2022 8-K Quarterly results
09/13/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "FORM 8-K",
"Recursion Initiates Two Additional Clinical Trials For a Total of Four in 2022"
08/09/2022 8-K Investor presentation, Quarterly results
Docs: "Recursion Provides Business Updates and Reports Second Quarter 2022 Financial Results",
"705 768 708 602 575 641 686 709 519 439 393 333 0 500 1,000 1,500 2,000 2,500 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021"
06/21/2022 8-K Quarterly results
06/16/2022 8-K Quarterly results
06/09/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
04/11/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "FORM 8-K",
"Recursion is Granted Fast Track Designation for REC-4881 for the Potential Treatment of Familial Adenomatous Polyposis"
03/23/2022 8-K Investor presentation
Docs: "Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2021 Financial Results",
"End of Q4 2021"
03/18/2022 8-K Quarterly results
03/03/2022 8-K Quarterly results
01/10/2022 8-K Investor presentation
Docs: "Investor presentation of Recursion Pharmaceuticals, Inc."
12/07/2021 8-K Quarterly results
12/06/2021 8-K Quarterly results
11/10/2021 8-K Investor presentation
Docs: "Recursion Provides Business Updates and Reports Third Quarter 2021 Financials",
"0 20 40 60 80 100 120 140 160 180 200 0 5 10 15 20 25 30 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 4"
10/07/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Recursion is Granted FDA Fast Track Designation for REC-2282 for the Potential Treatment of NF2-Mutated Meningiomas"
09/09/2021 8-K Quarterly results
08/13/2021 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Recursion Reports Second Quarter 2021 Financials and Provides Business Updates"
07/13/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Recursion Announces Therapeutics Advisory Board, Chaired by Joseph Miletich, MD, PhD Therapeutics Advisory Board to help guide Recursion's growing clinical pipeline through development SALT LAKE CITY, July 13, 2021 — Recursion , a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning and engineering, today announced its formation of a Therapeutics Advisory Board , chaired by Joseph Miletich, MD, PhD. The TAB will guide Recursion's executive team and Board of Directors on the key challenge of developing medicines at scale from its tech-enabled drug discovery pipeline and bringing them to the patients who need them the most. Most recently, Dr. Miletich was Merck Research Laboratories' senior vice..."
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy